Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Immunoglobulin Light-chain Amyloidosis 2Neoplasms, Plasma Cell 1Multiple Myeloma 1

Interventions

Melphalan 4sargramostim 3Peripheral Blood Stem Cell Transplantation 3Cyclophosphamide 3Interferon-alpha 2Filgrastim 2Dexamethasone 2Carboplatin 2Calcium Dobesilate 24'-deoxy-4'-iododoxorubicin 2venetoclax 1ixazomib 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1X-Rays 1Sunitinib 1Specimen Handling 1Radiotherapy 1Pharmacogenomic Testing 1Phantoms, Imaging 1Magnetic Resonance Spectroscopy 1Ketamine 1Interleukin-12 Subunit p35 1Imatinib Mesylate 1Ifosfamide 1Docetaxel 1Decitabine 1Busulfan 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Immunoglobulin Light-chain Amyloidosis × 4'-deoxy-4'-iododoxorubicin × Clear all
NCT00030381 2013-01-16

Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis

National Cancer Institute (NCI)

Phase 1 Terminated
22 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT00003853 2012-11-12

4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis

National Cancer Institute (NCI)

Phase 2 Completed
45 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡